Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.
about
Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope proteinHigh versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort studyInterferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtypeIgG1 anti-P2 as a marker of response to interferon in patients with chronic hepatitis CGB Virus C/Hepatitis G Virus (GBV-C/HGV): still looking for a diseaseHigh serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C.Methodological issues in papers on IFN therapy: time for reappraisal.Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.Molecular techniques for clinical diagnostic virologyViral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patientsChemoprevention of hepatocellular carcinoma: concept, progress and perspectives.New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination.Case selection for interferon treatment of hepatitis C.Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha.Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.Automation of polymerase chain reaction-based systems for detection of hepatitis C virus RNA.Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy.Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay.High-dose natural interferon-alpha therapy for chronic hepatitis C with a high viral load: predictors of efficacy. The Aomori, Akita and Iwate Areas Viral Hepatitis Research Group.Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0.Efficacy of interferon therapy in elderly patients with chronic hepatitis C.Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2.Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon-α and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1.
P2860
Q24338469-041516E2-1B88-4C95-B2E2-2F8105FA1E7DQ24799492-2F78FF1A-C7D5-4B46-8151-9313AA84D352Q27477854-E18C81C1-E0E1-4EF5-93C0-52AB8020D88DQ27480600-D6E43776-FB43-41CD-BEB8-20C48BB088C0Q27486644-62928BB2-EAA2-4380-804E-F5DD32550A78Q33788303-BAEC23FD-8619-4203-931C-83427BE5EE19Q33940500-2533BD33-9404-47AB-9008-2022C99BF8CDQ33988105-D5D77A5E-5771-4E09-8DB1-12CD94E67929Q34015058-8CCF5D50-1975-4894-A841-7A0B8869FFD4Q34129547-43E01190-8786-498D-98F0-8E87E02998D0Q34481770-2E33829E-304E-40F6-8A6C-6E2A4093DBD3Q34536138-932B79D2-AA6B-42BD-9A47-959195687E33Q34605687-FD72F3EE-7898-4CEA-B1B1-7BAC3902B2CFQ34621423-5002C594-AE92-495C-A1AA-811D4404FF6EQ35740155-30B8F399-3001-4F50-AD5A-A3E0762184C6Q36258740-FC187184-03F1-4AD7-959B-BEDC3B1A752DQ37356788-4C63B7BB-D0AC-4C08-A067-4BBF122CB7E2Q39458171-24C5A072-BCC0-43C0-9740-0316FE41BEAAQ40755017-84A2AE8D-5235-4232-ABE6-03F4AA86FD28Q42164795-58E66DC3-258D-4927-B1F0-F68F31D831A8Q42465048-0E07130B-DA26-45EA-930D-628C6741BD52Q42989123-173ED292-8FA3-46F9-BC13-5CF4418BC481Q42990511-35F4C586-D7A7-4928-8018-A29EEB5422BEQ42990741-C9FA96F1-28BD-4DA0-A307-60FBCCD16F16Q42991466-A1248D38-9668-4E8B-939D-C0DA50B66FF7Q42992697-E3B99E6B-16AE-43B8-B932-B70B9A6965F0Q42993577-2004D47B-087E-446C-9783-F5F256221EFEQ42994590-170F0DEA-15B1-4325-8B04-CD3F8A2D058EQ42997080-CD1675D0-1391-47F1-98D5-035B1871D3C3Q42997762-2F8A1326-8D96-4503-A99A-4B0B8465A75EQ42999698-04659713-592A-416D-AB7F-15D7F0689D51Q43000078-FF4B8153-7FFB-43BF-A2E6-A447493B099DQ43030767-27C57988-673F-4019-A15B-EF6E2E9B41ECQ43031195-3D50201E-835D-442D-B9DF-842B805B5691Q43031802-2B64D1B8-FE76-4AF6-B805-78ACF639ABBEQ43040005-F8B73CF1-3C99-49C3-B6BA-F9652DF2F5A3Q43041166-8CDCCD39-0C3D-4D41-950E-F7A3B14955B1Q43527754-3B0AE04D-FCD7-4F0A-B556-67DEDAFCA332Q43762372-5097C3FA-A184-4BBF-93DE-D3C22E4F4ABBQ45209851-45E5088E-07EE-4727-91EE-62D9B150403F
P2860
Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@en
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@nl
type
label
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@en
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@nl
prefLabel
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@en
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@nl
P2093
P1433
P1476
Predictors of the efficacy of ...... hiba Hepatitis Research Group.
@en
P2093
Hashimoto E
Nakamura A
Shiratori Y
P304
P356
10.1053/GAST.1997.V113.PM9247476
P407
P577
1997-08-01T00:00:00Z